Craig Portell is an Oncology physician affiliated with University of Virginia Health System. OpenAlex indexes 179 publications with 3,064 citations (h-index 28); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1240 Lee St
Charlottesville, VA 229080817
Telephone
434-924-9333Provider last certified this registry record 9 Aug 2023.
Clinical trials
- Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL
Sponsor: University of Virginia
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20254 payments
- Genentech USA, Inc.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
1 NIH research award on record, funded 2025–2025 per NIH RePORTER. The latest:
- A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin versus Investigator's Choice in Patients with Relapse or Refractory Periperal T-cell lymphoma (PTCL).
University of Virginia
FY2025$808,684R01FD006814
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma
Journal of Clinical Oncology
2025 - Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma
New England Journal of Medicine
2024 - Outcomes of patients with <scp>limited‐stage</scp> plasmablastic lymphoma: A <scp>multi‐institutional</scp> retrospective study
American Journal of Hematology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Frederick Hayden, MD
University of Virginia Health System
Allan Tsung, MD
University of Virginia Health System
Irving Kron, MD
University of Virginia Health System
Karen Ballen, MD
University of Virginia Health System
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”